人乳头瘤病毒阳性口咽癌降强度放化疗后的患者视角与治疗后悔:一项II期试验结果
该II期试验评估HPV阳性口咽癌降强度放化疗患者的优先事项、期望与后悔。27例中24例(89%)参与调查,中位随访24个月。23例(96%)将「治愈」或「尽可能延长生存」列为最高优先;无患者对入组降强度方案表示后悔;16例(67%)认为回顾性报告的长期吞咽功能优于或符合预期。
要点
- 23/24例(96%)将治愈或尽可能延长生存列为最高优先事项。
- 无患者对入组降强度放化疗方案表示后悔。
- 16/24例(67%)认为长期吞咽功能优于或符合预期。
核心结论
- 这些数据提供了HPV阳性口咽癌降强度治疗患者视角与优先事项的基线全景,并为建立新标准治疗的持续努力提供了支持。
研究设计与样本
- II期试验,纳入III/IV期口咽鳞状细胞癌、p16阳性、年龄≥18岁、Zubrod评分0-1的患者,采用经验证的量表进行患者调查。
主要发现
- 27例中24例(89%)参与调查,中位随访24个月。
- 23例(96%)选择「治愈」或「尽可能延长生存」为最高优先事项。
- 无患者报告对入组降强度方案的决定有任何后悔。
- 16例(67%)认为回顾性报告的长期吞咽功能优于或符合最初预期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated priorities, expectations, and regret among patients treated on a phase II trial of de-escalated chemoradiation for human papillomavirus (HPV)-positive oropharyngeal cancer. METHODS: Eligibility included stage III/IV squamous cell carcinoma of the oropharynx, p16-positivity, age ≥18 years, and Zubrod score 0-1. Participants were surveyed with validated measures evaluating their treatment experience. RESULTS: Twenty-four of 27 (89%) patients participated with a median follow-up of 24 months. Twenty-three subjects (96%) selected "being cured" or "living as long as possible" as top priority. No patient reported any regret about the decision to enroll on a de-escalation protocol. Sixteen participants (67%) found retrospectively reported long-term swallowing function to be either better than or as originally expected. CONCLUSIONS: These data offer a baseline landscape of perspectives and priorities for patients treated with de-escalation for HPV-positive oropharyngeal carcinoma and provide support to the fundamental premise underlying ongoing efforts to establish a new standard of care.
引用
- Shaverdian N, Hegde JV, Felix C, et al. Patient perspectives and treatment regret after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal cancer: Findings from a phase II trial. Head Neck. 2019. PMID: 30958605. doi:10.1002/hed.25760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。